Targeted Cancer Drugs
This article was originally published in Start Up
Executive Summary
In the past decade, a new paradigm has emerged in the form of drugs that target the genetic abnormalities that cause a normal cell to become cancerous. These targeted therapies are the fastest growing segment in the oncology market, and are poised to garner a respectable share of a global anti-cancer market projected to reach $70 billion by the end of this decade. Currently, there are 24 such compounds in Phase III clinical trials. The complex challenges in developing these drugs haven't deterred start-ups from entering the fray.